drug_type
RELEVANT_DRUG
intervention_type
Drug (antibody-drug conjugate)
drug_description
An anti-HER2 antibody-drug conjugate consisting of a recombinant anti-HER2 monoclonal antibody linked to a camptothecin-derived topoisomerase I inhibitor payload; upon binding HER2 and internalization, it releases the payload to inhibit Topo I, causing DNA damage and tumor cell death, and may also suppress HER2 signaling and engage Fc-mediated effector functions.
nci_thesaurus_concept_id
C198994
nci_thesaurus_definition
An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) conjugated to a camptothecin derivative, with potential antineoplastic activity. Upon administration of the anti-HER2 ADC IBI354, the anti-HER2 monoclonal antibody targets and binds to HER2 expressed on tumor cells. Upon cellular uptake, the camptothecin derivative inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and tumor cell apoptosis. This inhibits the proliferation of HER2-expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.
drug_mesh_term
Antibody-Drug Conjugates
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Anti-HER2 monoclonal antibody linked to a camptothecin-derived topoisomerase I inhibitor; binds HER2 and is internalized, then releases the payload to inhibit Topo I, causing DNA damage, cell-cycle arrest, and tumor cell death; may also suppress HER2 signaling and engage Fc-mediated effector functions.
drug_name
IBI354
nct_id_drug_ref
NCT05636215